Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome

Background: Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, with a complex pathophysiology. Antispasmodics are prescribed as first-line therapy because of their action on gut dysmotility. In this regard, peppermint oil also has antispasmodic properties.

Aim: To update our previous meta-analysis to assess efficacy and safety of peppermint oil, particularly as recent studies have cast doubt on its role in the treatment of IBS METHODS: We searched the medical literature up to 2nd April 2022 to identify randomised controlled trials (RCTs) of peppermint oil in IBS. Efficacy and safety were judged using dichotomous assessments of effect on global IBS symptoms or abdominal pain, and occurrence of any adverse event or of gastro-oesophageal reflux. Data were pooled using a random effects model, with efficacy and safety reported as pooled relative risks (RRs) with 95% confidence intervals (CIs).

Results: We identified 10 eligible RCTs (1030 patients). Peppermint oil was more efficacious than placebo for global IBS symptoms (RR of not improving = 0.65; 95% CI 0.43-0.98, number needed to treat [NNT] = 4; 95% CI 2.5-71), and abdominal pain (RR of abdominal pain not improving = 0.76; 95% CI 0.62-0.93, NNT = 7; 95% CI 4-24). Adverse event rates were significantly higher with peppermint oil (RR of any adverse event = 1.57; 95% CI 1.04-2.37).

Conclusions: Peppermint oil was superior to placebo for the treatment of IBS, but adverse events were more frequent, and quality of evidence was very low. Adequately powered RCTs of peppermint oil as first-line treatment for IBS are needed.

Keywords: RCT comparison; efficacy; irritable bowel syndrome; peppermint oil.

© 2022 John Wiley & Sons Ltd.

Comment in

Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Ingrosso MR, et al. Aliment Pharmacol Ther. 2022 Oct;56(7):1217-1218. doi: 10.1111/apt.17197. Aliment Pharmacol Ther. 2022. PMID: 36071007 No abstract available.

Gu Y, Xiang Y. Gu Y, et al. Aliment Pharmacol Ther. 2022 Oct;56(7):1215-1216. doi: 10.1111/apt.17194. Aliment Pharmacol Ther. 2022. PMID: 36071010 No abstract available.

Similar articles

Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, Ford AC. Black CJ, et al. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):117-131. doi: 10.1016/S2468-1253(19)30324-3. Epub 2019 Dec 16. Lancet Gastroenterol Hepatol. 2020. PMID: 31859183

Khanna R, MacDonald JK, Levesque BG. Khanna R, et al. J Clin Gastroenterol. 2014 Jul;48(6):505-12. doi: 10.1097/MCG.0b013e3182a88357. J Clin Gastroenterol. 2014. PMID: 24100754 Review.

Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Ruepert L, et al. Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD003460. doi: 10.1002/14651858.CD003460.pub3. Cochrane Database Syst Rev. 2011. PMID: 21833945 Free PMC article. Review.

Goodoory VC, Tuteja AK, Black CJ, Ford AC. Goodoory VC, et al. Clin Gastroenterol Hepatol. 2024 Feb;22(2):243-251.e5. doi: 10.1016/j.cgh.2023.02.014. Epub 2023 Feb 27. Clin Gastroenterol Hepatol. 2024. PMID: 36858143 Review.

Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JTW, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Keszthelyi D. Weerts ZZRM, et al. Gastroenterology. 2020 Jan;158(1):123-136. doi: 10.1053/j.gastro.2019.08.026. Epub 2019 Aug 27. Gastroenterology. 2020. PMID: 31470006 Clinical Trial.

Cited by

Layer P, Andresen V. Layer P, et al. Inn Med (Heidelb). 2024 Sep;65(9):955-961. doi: 10.1007/s00108-024-01754-8. Epub 2024 Aug 9. Inn Med (Heidelb). 2024. PMID: 39122926 Review. German.

Ford AC, Vanner S, Kashyap PC, Nasser Y. Ford AC, et al. Gastroenterology. 2024 Jun;166(6):976-994. doi: 10.1053/j.gastro.2024.01.045. Epub 2024 Feb 5. Gastroenterology. 2024. PMID: 38325759 Review.

Yuan Y, Wang X, Huang S, Wang H, Shen G. Yuan Y, et al. Gut Microbes. 2023 Dec;15(2):2263209. doi: 10.1080/19490976.2023.2263209. Epub 2023 Oct 2. Gut Microbes. 2023. PMID: 37786296 Free PMC article. Review.

Staudacher HM, Black CJ, Teasdale SB, Mikocka-Walus A, Keefer L. Staudacher HM, et al. Nat Rev Gastroenterol Hepatol. 2023 Sep;20(9):582-596. doi: 10.1038/s41575-023-00794-z. Epub 2023 Jun 2. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37268741 Free PMC article. Review.

Galgano F, Mele MC, Tolve R, Condelli N, Di Cairano M, Ianiro G, D'Antuono I, Favati F. Galgano F, et al. Foods. 2023 Feb 17;12(4):856. doi: 10.3390/foods12040856. Foods. 2023. PMID: 36832931 Free PMC article. Review.

References

REFERENCES

    1. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675-88.
    1. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150:1393-407.
    1. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229-39.
    1. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:908-17.
    1. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160:99-114.